Trial Search Results

Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms

The purpose of this study is to determine if telmisartan is effective in slowing the progression of abdominal aortic aneurysms and reducing circulating concentrations of Abdominal Aortic Aneurysms (AAA) biomarkers.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Palo Alto Veterans Institute for Research

Collaborator: Medtronic

Stanford Investigator(s):

Intervention(s):

  • Drug: Telmisartan
  • Drug: Placebo

Phase:

Phase 4

Eligibility


Inclusion Criteria:

   - 50-85 years of age and able to provide written informed consent

   - AAA measuring a maximum diameter of 3.5-4.9 cm on CTA or ultrasound

   - Stable medication regime for the last six months

   - No current indication for AAA repair according to the treating physician or
   expectation that this will be revised within the next year

   - High likelihood of compliance with treatment over 24 months

Exclusion Criteria:

   - Renal impairment (i.e. creatinine >1.5x upper limit of normal [ULN])

   - Known significant renal stenosis (>70%) of one or both renal arteries

   - Chronic liver disease (i.e. cirrhosis or hepatitis) or abnormal liver function (i.e.
   ALT 1.5xULN)

   - Electrolyte imbalance

   - Active gout

   - Current or planned usage of an AT1 blocker or ACE inhibitor

   - Previous abdominal aortic surgery

   - Currently pregnant or intend to become pregnant

Ages Eligible for Study

50 Years - 85 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Ronald Dalman
6507232169
Recruiting